Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
about
Lessons learned from more than 1,000 pancreas transplants at a single institutionEpstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic targetAnti-Epstein-Barr virus (EBV) activity of beta-L-5-iododioxolane uracil is dependent on EBV thymidine kinaseMurine gammaherpesvirus 68 infection is associated with lymphoproliferative disease and lymphoma in BALB beta2 microglobulin-deficient miceProphylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation.The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients.Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients.A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas.Central nervous system infection during immunosuppression.Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumorsEvaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.Post-transplant lymphoproliferative disorder: a review.Management of opportunistic infections in solid-organ transplantation.Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatmentManagement of patients with post-transplant lymphoproliferative disorder: the role of rituximab.Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.Strategies for the prevention of infection after solid organ transplantation.Recent advances in the understanding of infectious mononucleosis: are prospects improved for treatment or control?EBV reactivation as a target of luteolin to repress NPC tumorigenesis.A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results.Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers.How I treat EBV lymphoproliferation.Recent developments in the prevention and treatment of Epstein-Barr virus-associated lymphoproliferative diseases.Immunosuppression-related lymphomas and cancers in IBD: how can they be prevented?Opportunistic viral infections in intestinal transplantation.A review on comparing two commonly used rabbit anti-thymocyte globulins as induction therapy in solid organ transplantation.Production and characterisation of Epstein-Barr virus helicase-primase complex and its accessory protein BBLF2/3.The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review.Valganciclovir for the Suppression of Epstein-Barr Virus Replication.Identification of distinct subgroups of EBV-positive post-transplant diffuse large B-cell lymphoma.The mycotoxin aflatoxin B1 stimulates Epstein-Barr virus-induced B-cell transformation in in vitro and in vivo experimental models.Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus.Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.Prevention, detection, and management of early bacterial and fungal infections in a preclinical cardiac xenotransplantation model that achieves prolonged survival.Renal transplantation in children managed with lymphocyte depleting agents and low-dose maintenance tacrolimus monotherapy.Epstein-Barr virus-associated Hodgkin's disease following renal transplantation.EBV-associated recurrent Hodgkin's disease after renal transplantation.Ex vivo alloanergization with belatacept: a strategy to selectively modulate alloresponses after transplantation.
P2860
Q24541751-42F582B7-F64A-4008-98BA-32D53E53F091Q26822550-1A4899F4-577C-4F68-BB1E-67F3C6C29184Q28344936-DE42DD2F-7CF1-47EA-A799-2B4752ADCCF8Q34142912-97CFE9D2-F9B6-4599-8686-647C83654570Q34191785-B86CE208-2D80-404C-8E64-506B4C128626Q34244446-02419691-C44C-4193-9B48-B5D8531CCAA7Q34271690-38B45CA8-AE0D-4F84-93A5-00AFDFCD3FF8Q34457976-8E82169B-D6F9-433F-B9E9-E3AFD9C41C5DQ34469041-5188DFE1-EDEC-48BB-9A0F-B3BBDE54E3FAQ34622755-BFEA6E4A-5684-4CEE-8386-F5C2220D5809Q34767204-6F90FDC4-75D1-4BBA-9CC6-D446E8668E27Q34946254-3915E5B3-1BF9-4392-83DE-67455AFA35D1Q35079593-2539A735-C7F7-43E9-AD87-B6319C76281BQ35841369-86E10FCB-E1A1-4770-8BB6-A16F8C18F321Q35849039-BF656CF7-37A6-4ED2-A1F7-FC4AFB148EF1Q36170494-E44FA562-96B9-4C5D-A44A-739AA771880BQ36435819-D8991B77-8004-461C-BE35-E79D674F7335Q36556729-4915C6A5-FFC2-4516-84E0-1ADEE75604A5Q36670902-EA80FAD1-2517-4C23-9065-216160DA32A0Q36688962-C13B02C7-1917-46FD-9CDD-3AD22C91B0F4Q37109915-09CF6384-C81F-4BD8-A5F1-4948DA3DB71AQ37225674-C2ED36FC-EB39-43D2-B0A2-79B91233349DQ37410629-D80DD439-F2F2-4C1F-9D22-A1551E1EE8CEQ37414678-70BBA9DD-B87C-4390-99D2-341D40E82BACQ37906623-24033C8C-7826-4014-B520-34DE452883BAQ38026406-0921135B-E219-447D-8473-51F9E1ACA98AQ38097119-3C7D9947-C836-4C47-8755-A443F66721B8Q38123228-C8643E7B-9677-4CC9-8AFD-0DBD6626AAA0Q38842220-B3A36D73-4642-42DC-B802-661D173021D1Q38933152-6AD1DCA9-27C0-4805-8445-641E5270C2DDQ40071868-FEF4FDC0-4013-464D-B022-722A6D66FF53Q40383136-C67569FD-C67B-4084-85E7-18FD3128E890Q40479894-DA6FF96D-AD4A-4BD7-AE58-534216C4BBEAQ40487893-3142F09E-7A7D-4527-B945-1D47E7841BF1Q40491223-5BE5BDD6-3E87-4FE5-845E-CB310E23D737Q40515493-03BAC667-B078-4BF7-8748-5A99D9C4BE2BQ41810263-E1498B0C-D097-45FD-BB58-7E00D06A40F7Q41870332-8CAEE5FA-CCD1-40B7-BA48-6FBDE614ECEDQ42911133-677D1B09-D4DB-4004-A623-F506F2173193Q43655192-3D3AA4A4-3280-4DCB-AA36-D1EF0FAADA3E
P2860
Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Reduced incidence of Epstein-B ...... preemptive antiviral therapy.
@en
Reduced incidence of Epstein-B ...... preemptive antiviral therapy.
@nl
type
label
Reduced incidence of Epstein-B ...... preemptive antiviral therapy.
@en
Reduced incidence of Epstein-B ...... preemptive antiviral therapy.
@nl
prefLabel
Reduced incidence of Epstein-B ...... preemptive antiviral therapy.
@en
Reduced incidence of Epstein-B ...... preemptive antiviral therapy.
@nl
P2093
P1433
P1476
Reduced incidence of Epstein-B ...... preemptive antiviral therapy.
@en
P2093
Basadonna GP
Darenkov IA
Friedman AL
Marcarelli MA
P304
P356
10.1097/00007890-199709270-00010
P577
1997-09-01T00:00:00Z